Angiotensin II type 1 receptor mediates pulmonary hypertension and right ventricular remodeling induced by inhaled nicotine
Nicholas D. Fried, Tamara Morris, Anna Whitehead, Eric Lazartigues, Xinping Yue, Jason D. Gardner
Abstract
Chronic, inhaled nicotine causes pulmonary hypertension and right ventricular remodeling in mice. Treatment with losartan, an angiotensin II type 1 receptor antagonist, ameliorates nicotine-induced pulmonary hypertension and right ventricular remodeling. This novel finding provides preclinical evidence for the use of renin-angiotensin system-based therapies in the treatment of pulmonary hypertension, particularly in patients with a history of tobacco-product use.
Topics & Concepts
LosartanPulmonary hypertensionMedicineNicotineInternal medicineRight ventricular hypertrophyRenin–angiotensin systemCardiologyAngiotensin IIVentricular remodelingAngiotensin II receptor antagonistReceptorPharmacologyHeart failureBlood pressurePulmonary Hypertension Research and TreatmentsAsthma and respiratory diseasesRenin-Angiotensin System Studies